// App-Quantinova.ai

SAT0402 : EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE P19-SUBUNIT OF INTERLEUKIN-23, THROUGH WEEK 52 OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Researchers

Presenter

  • I. Mcinnes

Principal Investigators

  • P. Rahman

  • A. B. Gottlieb

  • E. C. Hsia

  • A. Kollmeier

  • X. L. Xu

  • R. A. Subramanian

  • P. Agarwal

  • S. Sheng

  • Y. Jiang

  • B. Zhou

  • D. Van der Heijde

  • P. J. Mease

Medical Centers

  • University of Glasgow, Glasgow, United Kingdom

  • Mem Univ of Newfoundland, St Johns, Canada

  • Icahn School of Med Mt Sinai, New York, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Perelman School of Medicine, Philadelphia, United States of America

  • Leiden University Medical Centre, Leiden, Netherlands

Locations

  • United Kingdom

  • Canada

  • United States

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • C reactive protein

  • Albumin/creatinine

Drug/Treatment

  • Interleukin

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved